Daunorubicin


Description

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Read more

Pharmacology

Indication

For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adul... Read more

Pharmacodynamic

Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this cl... Read more

Mechanism of action

Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of actio... Read more

Absorption

Information currently not available.

Protein binding

97% binding-albumin

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

18.5 hours

Route of elimination

Twenty-five percent of an administered dose of daunorubicin hydrochloride is eliminated in an active... Read more

Toxicity

LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Hyperuricemia US
Varying Reports
Chills US
Varying Reports
Contact dermatits US
Varying Reports
Urticaria US
Varying Reports
Reversible alopecia US
Varying Reports
Rash US
Varying Reports
Mucositis US
Varying Reports
Diarrhea US
Varying Reports
Nausea US
Varying Reports
Vomiting US
Varying Reports
Local tissue necrosis US
Varying Reports
Cellulitis US
Varying Reports
Abdominal Pain US
Varying Reports
Extravasation US
Varying Reports
Anaphylactoid reaction US
Varying Reports
Fever US
Varying Reports
Thrombophlebitis US
Varying Reports
Painful induration US
Varying Reports
Cardiotoxicity US
Varying Reports
Myelosuppression US
Varying Reports

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Daunorubicin

The serum concentration of (R)-warfarin can be increased when it is combined with Daunorubicin.
The serum concentration of (S)-Warfarin can be increased when it is combined with Daunorubicin.
The risk or severity of adverse effects can be increased when Daunorubicin is combined with 2-Methoxyethanol.
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Daunorubicin.
The metabolism of 4-hydroxycoumarin can be decreased when combined with Daunorubicin.
The metabolism of 5-androstenedione can be decreased when combined with Daunorubicin.
The metabolism of Daunorubicin can be decreased when combined with 6-Deoxyerythronolide B.
The metabolism of 6-O-benzylguanine can be decreased when combined with Daunorubicin.
The metabolism of 7-ethyl-10-hydroxycamptothecin can be decreased when combined with Daunorubicin.
The risk or severity of adverse effects can be increased when Daunorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
The metabolism of 9-aminocamptothecin can be decreased when combined with Daunorubicin.
The metabolism of Daunorubicin can be increased when combined with Abatacept.
The risk or severity of bleeding can be increased when Abciximab is combined with Daunorubicin.
The serum concentration of Abemaciclib can be increased when it is combined with Daunorubicin.
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abetimus.
The metabolism of Abiraterone can be decreased when combined with Daunorubicin.
The metabolism of Daunorubicin can be decreased when combined with Acalabrutinib.
The serum concentration of Acebutolol can be increased when it is combined with Daunorubicin.
The serum concentration of Acenocoumarol can be increased when it is combined with Daunorubicin.
The serum concentration of Daunorubicin can be increased when it is combined with Acetaminophen.

References

    Information currently not available.

Recent Questions